Learn Before
Concept
Results of CoVLP Phase 1 Trial
- all dosages and combinations were well-tolerated, but adjuvants significantly increased reactogenicity (especially after dose 2)
- CoVLP+AS03(adjuvant) had the most severe and frequent adverse. This group also had the highest immunogenicity after dose 1.
- After the first dose, only a weak humoral response. After the second dose, modest cellular responses were elicited.
0
1
Updated 2020-11-23
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences